Rosuvastatin

Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].

Product Specifications

CAS Number

[287714-41-4]

Product Name Alternative

ZD 4522

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Bacterial; HMG-CoA Reductase (HMGCR) ; Potassium Channel

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/rosuvastatin.html

Purity

99.67

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2

Molecular Formula

C22H28FN3O6S

Molecular Weight

481.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5 (2) : p. 437-44.|[2]Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101 (2) :868-78.|[3]Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16 (4) :1477-1488.|[4]Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62 (14) : p. 2075-85; discussion 2086-7.